Understand the source comparison
Best Peptides for Sjogren Syndrome: Research Comparison
Before choosing a research peptide, understanding the mechanism, evidence base, and practical constraints matters more than marketing claims. This table compares the most studied peptides for Sjogren's-related pathology. Thymalin T-regulatory cell induction vi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before choosing a research peptide, understanding the mechanism, evidence base, and practical constraints matters more than marketing claims. This table compares the most studied peptides for Sjogren's-related pathology.
- Thymalin
- T-regulatory cell induction via thymulin receptor agonism; restores CD4+/CD8+ ratio
- Preclinical + small human trials in autoimmune conditions
- 5–10mg SC every other day × 10–20 doses
- 2–8°C after reconstitution; <6 hour half-life
- Strongest evidence for immune recalibration in autoimmune states; requires consistent dosing
- BPC-157
- Mucosal healing, VEGF upregulation, NF-kB inhibition, FAK-paxillin pathway modulation
- Extensive animal models; no controlled human trials in Sjogren's
- 250–500mcg SC daily × 4–6 weeks
- 2–8°C after reconstitution; stable lyophilized at room temp
- Best-studied for tissue repair and anti-inflammatory action; oral/ocular mucosal benefits likely
- Cerebrolysin
- Neurotrophic factor delivery (BDNF, NGF); supports cholinergic nerve function and autonomic signaling
- Human trials in neuropathy; theoretical for Sjogren's nerve damage
- 5–30mL IV daily × 10–20 sessions
- Refrigerate vials; single-use ampules preferred
- Addresses autonomic nerve dysfunction affecting gland secretion; requires IV access
- KPV
- NF-kB translocation inhibitor; reduces systemic inflammatory cytokine production
- Animal models in IBD; minimal human data
- 500mcg–2mg SC daily
- 2–8°C after reconstitution
- Potent anti-inflammatory; most useful as adjunct to other peptides
- Dihexa
- BDNF mimetic; oral bioavailability; CNS and peripheral nerve support
- Preclinical cognitive models; no autoimmune trials
- 5–10mg oral daily (research doses vary widely)
- Room temperature as powder; refrigerate solutions
- Theoretical autonomic benefit; lacks direct Sjogren's evidence